ArticleJournal of the National Cancer Institute2021
Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation.
Article in Journal of the National Cancer Institute, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 83 citations in OpenAlex.
- Trial
- The prevalence and predictors of previous prostate cancer screening among men attending primary healthcare centers in Riyadh, Saudi Arabia.Annals of medicine · 2026Article
- Prostate Cancer Screening Among Traditionally Underserved Populations at a Large Public Safety-Net Institution.Journal of general internal medicine · 2026Article
- Negative perceptions of the health system and racial inequities in PSA screening.Prostate cancer and prostatic diseases · 2026Article
- Multilevel associations between prostate cancer testing and socioeconomic position: a population-based register study from Stockholm, Sweden.BMJ public health · 2026Article
- Comparing Black and White Patients in Treatment of Advanced Prostate Cancer and Survival in an Equal Access Health System.Journal of racial and ethnic health disparities · 2025Article
- Real-world analyses of major adverse cardiovascular events and mortality risk after androgen deprivation therapy initiation in black vs. white prostate cancer patients.Prostate cancer and prostatic diseases · 2025Article
- Rising metastatic prostate cancer rates but narrowing racial gap.BMC medicine · 2025Article
- Geographic and Temporal Patterns of Screening for Breast, Cervical, and Colorectal Cancer in the US, 1997-2019.JAMA network open · 2025Article
- Patient and Physician Perceptions of Prostate-Specific Antigen Testing Among Black Individuals.JAMA network open · 2025Article
- Article
- Understanding Racial Disparities in Prostate Cancer: A Multifaceted Approach.Cancer medicine · 2025Review
- Trends in stage-specific prostate cancer incidence by neighborhood socioeconomic status.JNCI cancer spectrum · 2025Article
- Exploring prostate-specific antigen (PSA) Testing rates and screening disparities in the all of us dataset.Urologic oncology · 2025Article
- Exploration of social determinants of health and prostate cancer prevalence in the US: a cross-sectional study of NHANES data from 2003 to 2010.Frontiers in public health · 2025Article
- Prostate-specific antigen testing in the United States during 2008-2022 in relation to the US preventive services task force recommendations.Scientific reports · 2024Article
- A pilot randomized clinical trial of a smartphone-based application to support at-home PSA screening and culturally tailored prostate cancer education for African American men: A study protocol.Contemporary clinical trials · 2024Article
- Receipt of Prostate-Specific Antigen Test in Medicaid Beneficiaries With and Without HIV in 2001-2015 in 14 States.AIDS research and human retroviruses · 2024Article
- Multidimensional Healthcare Access Barriers to Prostate-Specific Antigen Testing: A Nation-Wide Panel Study in the United States From 2006 to 2020.Cancer medicine · 2024Article
- Determinants of receipt of prostate cancer screening among men living with HIV enrolled in an urban HIV Clinic in the United States over the period of 2000-2020.Preventive medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe 2012 US Preventive Services Task Force recommendation against routine prostate-specific antigen (PSA) testing led to a decrease in prostate cancer screening, but the heterogeneity of its impact by race and ethnicity remains unclear.
methodsThe proportion of 40- to 74-year-old men who self-reported receiving a routine PSA test in the past year was estimated in the Behavioral Risk Factor Surveillance System (2012-2018). Odds ratios (ORs) of undergoing screening by race and ethnicity were estimated, adjusting for healthcare-related factors. Prostate cancer incidence rates and rate ratios (IRRs) by race and ethnicity were estimated using Surveillance, Epidemiology, and End Results registry data (2004-2017).
resultsPSA testing frequencies were 32.3% (95% confidence interval [CI] = 31.7% to 32.8%) among non-Hispanic White (NHW), 30.3% (95% CI = 28.3% to 32.3%) among non-Hispanic Black (NHB), 21.8% (95% CI = 19.9% to 23.7%) among Hispanic, and 17.7% (95% CI = 14.1% to 21.3%) among Asian and Pacific Islander men in 2012. The absolute screening frequency declined by 9.5% from 2012 to 2018, with a larger decline among NHB (11.6%) than NHW men (9.3%). The relative annual decrease was greater among NHB (OR = 0.86, 95% CI = 0.84 to 0.88) than NHW men (OR = 0.89, 95% CI = 0.89 to 0.90; Pheterogeneity = .005), driven by a larger decline among NHB men ages 40-54 years. The NHB to NHW IRR for total prostate cancer increased from 1.73 (95% CI = 1.69 to 1.76) in 2011 to 1.87 (95% CI = 1.83 to 1.92) in 2012 and has remained elevated, driven by differences in localized tumor incidence. Metastatic disease incidence is rising across all racial and ethnic groups.
conclusionsThe frequency of prostate cancer screening varies by race and ethnicity, and there was a modestly steeper decline in PSA testing among younger NHB men relative to NHW men since 2012. The NHB to NHW IRR for localized prostate cancer modestly increased following 2012.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.